In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price.
As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. The following is a recap of.
As we previously reported, Magistrate Judge Hall issued a Report and Recommendation (“R&R”) on February 10, 2023 denying Amgen’s motion to dismiss Regeneron’s antitrust claims in.
While Delawareans are proud of the well-deserved elevation of Judge Stark to the Federal Circuit, his absence coupled with the District of Delaware's heavy caseload is forcing the Court.
While Delawareans are proud of the well-deserved elevation of Judge Stark to the Federal Circuit, his absence coupled with the District of Delaware’s heavy caseload is forcing the Court.